Cargando…
Elevated high-sensitivity troponin T levels at 1-year follow-up are associated with increased long-term mortality after TAVR
BACKGROUND: Elevated pre-procedural high-sensitivity troponin T (hs-TnT) levels predict adverse outcomes in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR). It is unknown whether elevated troponin levels still provide prognostic information during f...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907029/ https://www.ncbi.nlm.nih.gov/pubmed/33098469 http://dx.doi.org/10.1007/s00392-020-01759-x |
_version_ | 1783655410092212224 |
---|---|
author | Seoudy, Hatim Lambers, Moritz Winkler, Vincent Dudlik, Linnea Freitag-Wolf, Sandra Frank, Johanne Kuhn, Christian Rangrez, Ashraf Yusuf Puehler, Thomas Lutter, Georg Bramlage, Peter Frey, Norbert Frank, Derk |
author_facet | Seoudy, Hatim Lambers, Moritz Winkler, Vincent Dudlik, Linnea Freitag-Wolf, Sandra Frank, Johanne Kuhn, Christian Rangrez, Ashraf Yusuf Puehler, Thomas Lutter, Georg Bramlage, Peter Frey, Norbert Frank, Derk |
author_sort | Seoudy, Hatim |
collection | PubMed |
description | BACKGROUND: Elevated pre-procedural high-sensitivity troponin T (hs-TnT) levels predict adverse outcomes in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR). It is unknown whether elevated troponin levels still provide prognostic information during follow-up after successful TAVR. We evaluated the long-term implications of elevated hs-TnT levels found at 1-year post-TAVR. METHODS AND RESULTS: The study included 349 patients who underwent TAVR for severe AS from 2010–2019 and for whom 1-year hs-TnT levels were available. Any required percutaneous coronary interventions were performed > 1 week before TAVR. The primary endpoint was survival time starting at 1-year post-TAVR. Optimal hs-TnT cutoff for stratifying risk, identified by ROC analysis, was 39.4 pg/mL. 292 patients had hs-TnT < 39.4 pg/mL (median 18.3 pg/mL) and 57 had hs-TnT ≥ 39.4 pg/mL (median 51.2 pg/mL). The high hs-TnT group had a higher median N-terminal pro-B-type natriuretic peptide (NT-proBNP) level, greater left ventricular (LV) mass, higher prevalence of severe diastolic dysfunction, LV ejection fraction < 35%, severe renal dysfunction, and more men compared with the low hs-TnT group. All-cause mortality during follow-up after TAVR was significantly higher among patients who had hs-TnT ≥ 39.4 pg/mL compared with those who did not (mortality rate at 2 years post-TAVR: 12.3% vs. 4.1%, p = 0.010). Multivariate analysis identified 1-year hs-TnT ≥ 39.4 pg/mL (hazard ratio 2.93, 95% CI 1.91–4.49, p < 0.001), NT-proBNP level > 300 pg/mL, male sex, an eGFR < 60 mL/min/1.73 m(2) and chronic obstructive pulmonary disease as independent risk factors for long-term mortality after TAVR. CONCLUSIONS: Elevated hs-TnT concentrations at 1-year after TAVR were associated with a higher long-term mortality. GRAPHIC ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-7907029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-79070292021-03-09 Elevated high-sensitivity troponin T levels at 1-year follow-up are associated with increased long-term mortality after TAVR Seoudy, Hatim Lambers, Moritz Winkler, Vincent Dudlik, Linnea Freitag-Wolf, Sandra Frank, Johanne Kuhn, Christian Rangrez, Ashraf Yusuf Puehler, Thomas Lutter, Georg Bramlage, Peter Frey, Norbert Frank, Derk Clin Res Cardiol Original Paper BACKGROUND: Elevated pre-procedural high-sensitivity troponin T (hs-TnT) levels predict adverse outcomes in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR). It is unknown whether elevated troponin levels still provide prognostic information during follow-up after successful TAVR. We evaluated the long-term implications of elevated hs-TnT levels found at 1-year post-TAVR. METHODS AND RESULTS: The study included 349 patients who underwent TAVR for severe AS from 2010–2019 and for whom 1-year hs-TnT levels were available. Any required percutaneous coronary interventions were performed > 1 week before TAVR. The primary endpoint was survival time starting at 1-year post-TAVR. Optimal hs-TnT cutoff for stratifying risk, identified by ROC analysis, was 39.4 pg/mL. 292 patients had hs-TnT < 39.4 pg/mL (median 18.3 pg/mL) and 57 had hs-TnT ≥ 39.4 pg/mL (median 51.2 pg/mL). The high hs-TnT group had a higher median N-terminal pro-B-type natriuretic peptide (NT-proBNP) level, greater left ventricular (LV) mass, higher prevalence of severe diastolic dysfunction, LV ejection fraction < 35%, severe renal dysfunction, and more men compared with the low hs-TnT group. All-cause mortality during follow-up after TAVR was significantly higher among patients who had hs-TnT ≥ 39.4 pg/mL compared with those who did not (mortality rate at 2 years post-TAVR: 12.3% vs. 4.1%, p = 0.010). Multivariate analysis identified 1-year hs-TnT ≥ 39.4 pg/mL (hazard ratio 2.93, 95% CI 1.91–4.49, p < 0.001), NT-proBNP level > 300 pg/mL, male sex, an eGFR < 60 mL/min/1.73 m(2) and chronic obstructive pulmonary disease as independent risk factors for long-term mortality after TAVR. CONCLUSIONS: Elevated hs-TnT concentrations at 1-year after TAVR were associated with a higher long-term mortality. GRAPHIC ABSTRACT: [Image: see text] Springer Berlin Heidelberg 2020-10-24 2021 /pmc/articles/PMC7907029/ /pubmed/33098469 http://dx.doi.org/10.1007/s00392-020-01759-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Paper Seoudy, Hatim Lambers, Moritz Winkler, Vincent Dudlik, Linnea Freitag-Wolf, Sandra Frank, Johanne Kuhn, Christian Rangrez, Ashraf Yusuf Puehler, Thomas Lutter, Georg Bramlage, Peter Frey, Norbert Frank, Derk Elevated high-sensitivity troponin T levels at 1-year follow-up are associated with increased long-term mortality after TAVR |
title | Elevated high-sensitivity troponin T levels at 1-year follow-up are associated with increased long-term mortality after TAVR |
title_full | Elevated high-sensitivity troponin T levels at 1-year follow-up are associated with increased long-term mortality after TAVR |
title_fullStr | Elevated high-sensitivity troponin T levels at 1-year follow-up are associated with increased long-term mortality after TAVR |
title_full_unstemmed | Elevated high-sensitivity troponin T levels at 1-year follow-up are associated with increased long-term mortality after TAVR |
title_short | Elevated high-sensitivity troponin T levels at 1-year follow-up are associated with increased long-term mortality after TAVR |
title_sort | elevated high-sensitivity troponin t levels at 1-year follow-up are associated with increased long-term mortality after tavr |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907029/ https://www.ncbi.nlm.nih.gov/pubmed/33098469 http://dx.doi.org/10.1007/s00392-020-01759-x |
work_keys_str_mv | AT seoudyhatim elevatedhighsensitivitytroponintlevelsat1yearfollowupareassociatedwithincreasedlongtermmortalityaftertavr AT lambersmoritz elevatedhighsensitivitytroponintlevelsat1yearfollowupareassociatedwithincreasedlongtermmortalityaftertavr AT winklervincent elevatedhighsensitivitytroponintlevelsat1yearfollowupareassociatedwithincreasedlongtermmortalityaftertavr AT dudliklinnea elevatedhighsensitivitytroponintlevelsat1yearfollowupareassociatedwithincreasedlongtermmortalityaftertavr AT freitagwolfsandra elevatedhighsensitivitytroponintlevelsat1yearfollowupareassociatedwithincreasedlongtermmortalityaftertavr AT frankjohanne elevatedhighsensitivitytroponintlevelsat1yearfollowupareassociatedwithincreasedlongtermmortalityaftertavr AT kuhnchristian elevatedhighsensitivitytroponintlevelsat1yearfollowupareassociatedwithincreasedlongtermmortalityaftertavr AT rangrezashrafyusuf elevatedhighsensitivitytroponintlevelsat1yearfollowupareassociatedwithincreasedlongtermmortalityaftertavr AT puehlerthomas elevatedhighsensitivitytroponintlevelsat1yearfollowupareassociatedwithincreasedlongtermmortalityaftertavr AT luttergeorg elevatedhighsensitivitytroponintlevelsat1yearfollowupareassociatedwithincreasedlongtermmortalityaftertavr AT bramlagepeter elevatedhighsensitivitytroponintlevelsat1yearfollowupareassociatedwithincreasedlongtermmortalityaftertavr AT freynorbert elevatedhighsensitivitytroponintlevelsat1yearfollowupareassociatedwithincreasedlongtermmortalityaftertavr AT frankderk elevatedhighsensitivitytroponintlevelsat1yearfollowupareassociatedwithincreasedlongtermmortalityaftertavr |